Join ALZpath at Clinical Trials on Alzheimer’s Disease (CTAD) Dec. 1-4 in San Diego

News

Media Inquiries: media@alzpath.bio

November 6, 2025

ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for ‘Diagnostics Innovation of the Year’

July 28, 2025

Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment

April 7, 2025

ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics

April 1, 2025

Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis

March 25, 2025

ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor

March 18, 2025

ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

January 27, 2025

ALZpath Appoints Mike Banville as CEO

November 18, 2024

Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research

October 30, 2024

ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024

July 29, 2024

New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis

July 15, 2024

ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease

July 9, 2024

ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer

June 10, 2024

ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease

February 29, 2024

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research

January 22, 2024

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain

July 18, 2023

ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay

November 28, 2022

ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood